Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
关于子公司收到药品注册证书及药品补充申请批准通知书的公告
Regulatory Filings Classification · 90% confidence The document is an official announcement by a listed company regarding its subsidiary receiving drug registration certificates and supplemental approval notices from China’s National Medical Products Administration. It contains no financial statements, no meeting materials, no capital changes, not a dividend notice, not an interim or annual report, nor any proxy or merger filing. It is a typical regulatory event announcement that does not fit into any more specific category. Therefore, it should be classified under the fallback category “Regulatory Filings” (RNS).
2026-05-22 Chinese
2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 94% confidence The document is a formal announcement by 福安药业 detailing the 2025 annual equity distribution (dividend) plan, including dividend per share, record date, ex‐dividend date, payment method, and tax handling. This matches the definition of a Notice of Dividend Amount, which announces dividend amounts and payment details. Therefore, it should be classified as DIV.
2026-05-20 Chinese
2025年年度股东会决议公告
Regulatory Filings
2026-05-19 Chinese
东方华银关于福安药业2025年年度股东会之法律意见书
Regulatory Filings Classification · 90% confidence The document is a legal opinion letter (“法律意见书”) issued by an external law firm regarding the convening, procedure, attendee qualifications, voting process and results of the 2025 Annual General Shareholders Meeting. It primarily serves as a certification/attestation of procedural compliance under company and securities law, rather than being the AGM materials (like presentations) themselves or merely a vote-result notice. Under the “CERTIFICATION RULE,” a standalone legal opinion or attestation letter (even if it contains voting results) should be classified as a general regulatory/compliance filing. Therefore, the proper category is Regulatory Filings (RNS).
2026-05-19 Chinese
关于子公司收到药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about its subsidiary receiving a drug registration certificate from the national drug regulatory authority. It contains no financial data, no discussion of financial results, no management commentary on earnings, no meeting materials, no voting results, no legal proceedings, no capital changes, and no executive changes. The document is a regulatory announcement informing investors about a non-financial event related to product registration and market impact risks. It is short (662 characters) and serves as a formal disclosure rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-01-26 Chinese
2026年第一次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement from a company's first extraordinary general meeting (EGM) in 2026. It details the meeting date, attendance, voting results on a specific proposal (changing the audit firm for the 2025 fiscal year), and includes legal opinions confirming the meeting's compliance with laws and regulations. The content focuses on the official voting results and resolutions passed at the shareholders' meeting. There is no detailed financial data or full report content, but rather the formal announcement of the voting outcomes and resolutions. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (1902 characters), consistent with a voting results announcement rather than a full report or presentation.
2026-01-06 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.